LXEO
Lexeo Therapeutics, Inc. Common StockHealthcare·Biotechnology
$5.14
$404M market cap
Revenue
$0.0M
Free Cash Flow
$-41.3M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate f
2-Year Price History
$5.11-70.4%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -21.8 | -22.3 | -20.2 | -21.1 | -21.2 | -0.0 | 71.8 | 7.4 | 81.2 | -125.6% | -1281.6x | -- |
| Act | 2025-Q4 | 0.0 | -20.4 | -23.1 | -20.9 | -20.1 | -20.1 | -0.0 | 181.8 | 7.9 | 76.4 | -105.0% | -814.2x | -- |
Valuation & Metrics
Market Stats
Price$5.14
Market Cap$404M
Enterprise Value$339M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-10.2%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-41.1M
Free Cash Flow$-41.3M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-115.3%
WC Change % Rev0.0%
Interest Coverage-1003.4x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares13.1M
Days to Cover18.9
Change (vs Prior)+3.7%
Need at least 2 settlement dates for chart
Employees
Headcount75
Revenue / Employee$0
Gross Profit / Employee$-7,280
Cash Runway
20.9months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
88.8%(+68.2% YoY)
121 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
22.0%(+18.5% YoY)
10 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.3% YoY)
7 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | $35.5M | $8.97 | +$8.2M | +$35.5M | +2.0% | $4.69B |
| BlackRock, Inc.Passive | $29.3M | $9.11 | +$1.2M | +$18.8M | -0.2% | $5.69T |
| Affinity Asset Advisors, LLC | $29.0M | $4.56 | +$10.6M | +$20.5M | +0.6% | $1.60B |
| RA CAPITAL MANAGEMENT, L.P. | $28.7M | $10.69 | +$0 | +$25.6M | -4.4% | $9.44B |
| JANUS HENDERSON GROUP PLC | $28.5M | $10.12 | −$3.1M | +$2.4M | +1.2% | $209.29B |
| Vestal Point Capital, LP | $25.7M | $8.05 | +$0 | +$19.2M | +0.0% | $3.58B |
| Frazier Life Sciences Management, L.P. | $25.4M | $5.35 | +$0 | +$19.9M | +2.3% | $3.89B |
| CITADEL ADVISORS LLC | $22.0M | $10.98 | +$348K | +$6.4M | -0.4% | $138.22B |
| ORBIMED ADVISORS LLC | $20.7M | $8.21 | +$8.5M | +$20.7M | -8.1% | $4.38B |
| STATE STREET CORPPassive | $20.5M | $9.48 | +$2.2M | +$17.8M | -0.2% | $2.89T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $17.3M | $5.74 | +$17.3M | +$17.3M | — | $4.04T |
| Woodline Partners LP | $15.8M | $8.29 | −$2.6M | +$11.0M | -0.1% | $26.43B |
| GOLDMAN SACHS GROUP INC | $11.2M | $7.35 | +$6.7M | +$10.7M | -0.2% | $760.93B |
| Avoro Capital Advisors LLC | $10.8M | $9.93 | −$8.2M | +$10.8M | +1.3% | $10.15B |
| Point72 Asset Management, L.P. | $9.6M | $6.54 | −$1.2M | +$3.3M | +0.9% | $54.88B |
| MILLENNIUM MANAGEMENT LLC | $9.3M | $5.92 | +$4.0M | +$3.1M | -0.5% | $127.40B |
| BALYASNY ASSET MANAGEMENT LLC | $9.1M | $4.02 | −$261K | +$9.1M | -0.4% | $48.01B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $8.7M | $10.16 | +$390K | +$5.3M | +2.3% | $1.61T |
| ADAR1 Capital Management, LLC | $8.4M | $6.68 | +$426K | +$7.4M | +8.4% | $1.64B |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $7.2M | $9.93 | +$0 | +$7.2M | -9.0% | $3.69B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+0.34%
avg per quarter
Holders (ex-self)
+0.38%
excl. this stock
Buyers (this Q)
+12.21%
41 buyers · $0.04B in
Sellers (this Q)
+0.62%
38 sellers · $0.11B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+14.2%
how holders react when this stock falls
On quiet Qs
+43.4%
−10% to +10% baseline
On rallies (+10%+)
+7.9%
how they react when this stock rises
Holders' portfolio flow this Q
+3.7%
inflows — adds are organic
Sellers' portfolio flow this Q
+0.8%
Sellers' overall flow ~ flat.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.4%
Holder mid (any stock)
-1.0%
Holder rally (any stock)
-7.9%
Biggest decreases this quarter
Avoro Capital Advisors LLC−$8.2Mα+1.3Siren, L.L.C.exited−$7.2MSILVERARC CAPITAL MANAGEMENT, LLCexited−$6.1MVerition Fund Management LLCexited−$4.3MOctagon Capital Advisors LP−$3.6Mα+1.0JANUS HENDERSON GROUP PLC−$3.1Mα+1.2Woodline Partners LP−$2.6Mα-0.1AMERIPRISE FINANCIAL INCexited−$2.4MRENAISSANCE TECHNOLOGIES LLCexited−$2.2MJANE STREET GROUP, LLCexited−$1.4M
New buyers this quarter
Top-5 holders · 32.9%
Paradigm Biocapital Advisors LP--
BlackRock, Inc.--
Affinity Asset Advisors, LLC--
RA CAPITAL MANAGEMENT, L.P.--
JANUS HENDERSON GROUP PLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
JANUS HENDERSON GROUP PLC5.0MEVENTIDE ASSET MANAGEMENT, LLC—RA CAPITAL MANAGEMENT, L.P.5.0MParadigm Biocapital Advisors LP6.2MVestal Point Capital, LP4.5MFrazier Life Sciences Management, L.P.4.4MADAGE CAPITAL PARTNERS GP, L.L.C.—CITADEL ADVISORS LLC3.8MD1 Capital Partners L.P.—Omega Fund Management, LLC—
Analyst Coverage
Analyst Coverage
Price Targets
Last Year (9 analysts)$18.7826540.0%
Current Price$5.14
Analyst Ratings
5
Buy: 5Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$725K
20 txns · 5 insiders · 110,111 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | SELL | Otero Jose Manuel | officer: Chief Operating Officer | 1,302 | $5.07 | $7K | $660K |
| 2026-05-18 | SELL | Townsend Richard Nolan | director, officer: Chief Executive Officer | 3,342 | $5.06 | $17K | $1.71M |
| 2026-04-06 | SELL | Townsend Richard Nolan | director, officer: Chief Executive Officer | 55,000 | $5.69 | $313K | $1.94M |
| 2026-02-18 | SELL | Otero Jose Manuel | officer: Chief Operating Officer | 3,016 | $6.40 | $19K | $803K |
| 2026-02-18 | SELL | Townsend Richard Nolan | director, officer: Chief Executive Officer | 10,173 | $6.38 | $65K | $2.50M |
| 2025-11-18 | SELL | Adler Eric | officer: Chief Medical Officer | 615 | $9.27 | $6K | $673K |
| 2025-11-18 | SELL | Otero Jose Manuel | officer: Chief Operating Officer | 721 | $9.27 | $7K | $588K |
| 2025-11-18 | SELL | Robertson Jenny | officer: Chief Legal Officer | 549 | $9.27 | $5K | $634K |
| 2025-11-18 | SELL | See Tai Sandi | officer: Chief Development Officer | 386 | $9.27 | $4K | $607K |
| 2025-11-18 | SELL | Townsend Richard Nolan | director, officer: Chief Executive Officer | 1,127 | $9.27 | $10K | $2.23M |
| 2025-10-17 | SELL | See Tai Sandi | officer: Chief Development Officer | 3,888 | $8.94 | $35K | $589K |
| 2025-10-17 | SELL | Townsend Richard Nolan | director, officer: Chief Executive Officer | 13,133 | $8.94 | $117K | $2.17M |
| 2025-10-17 | SELL | Adler Eric | officer: Chief Medical Officer | 3,382 | $8.94 | $30K | $655K |
| 2025-10-17 | SELL | Robertson Jenny | officer: Chief Legal Officer | 3,526 | $8.94 | $32K | $616K |
| 2025-10-17 | SELL | Otero Jose Manuel | officer: Chief Technical Officer | 2,115 | $8.94 | $19K | $574K |
| 2025-08-18 | SELL | Adler Eric | officer: Chief Medical Officer | 608 | $4.67 | $3K | $313K |
| 2025-08-18 | SELL | Otero Jose Manuel | officer: Chief Technical Officer | 3,569 | $5.60 | $20K | $338K |
| 2025-08-18 | SELL | Robertson Jenny | officer: Chief Legal Officer | 542 | $4.67 | $3K | $292K |
| 2025-08-18 | SELL | See Tai Sandi | officer: Chief Development Officer | 382 | $4.67 | $2K | $275K |
| 2025-08-18 | SELL | Townsend Richard Nolan | director, officer: Chief Executive Officer | 2,735 | $4.67 | $13K | $1.03M |
Order Flow (FINRA, ~3w lag)
10.9%retail+8.6pp
20.9%dark-4.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
LXEO: The Dilution Engine – Funding Life-Saving Science through Relentless Equity Issuance
Overall Risk
7/10
Fraud
3/10
Dilution
10/10
Insolvency
6/10
Earnings Overstated
4/10
Hidden Liabilities
5/10
Legal
2/10
Audit Warnings
4/10
Hidden Upside
6/10
Contextually Acceptable
7/10